FibroGen to Report Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015
- S&P 500, Dow end at record highs as weak jobs data eases rate worries
- U.S. Added Only 266,000 Jobs in April, Well Below Estimates
- Roku (ROKU) Surges After Crushing Profit Estimates to Prompt an Upgrade to 'Buy' at Loop Capital
- Dollar broadly weaker after U.S. jobs data disappoint
- Square (SQ) Tops Q1 EPS by 25c
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Conference Call and Webcast Scheduled for 4:30 p.m. ET (1:30 p.m. PT)
SAN FRANCISCO--(BUSINESS WIRE)-- FibroGen, Inc. (NASDAQ: FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of four weeks.
Live (U.S. / Canada): (800) 708-4540
Live (International): (847) 619-6397
Confirmation number: 39222014
FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia in chronic kidney disease patients who are dialysis-dependent, including hemodialysis and peritoneal dialysis, and not dialysis-dependent.
Greg Mann, 415-978-1433
Source: FibroGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Expedia (EXPE) Flies Higher After Topping Analysts' Estimates, Analysts Raise Numbers and PT on 'Significant Outperformance'
- BevCanna Signs Third Consecutive White-Label Manufacturing Agreement
- 26 Million COVID-19 Vaccine Doses Mobilized Through Global Citizen's VAX LIVE: The Concert To Reunite The World From Governments, Philanthropists & The Private Sector Plus An Additional $302m For
Create E-mail Alert Related CategoriesPress Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!